, Protocol Review and Monitoring System (PRMS) The Scientific Review Committee (SRC) and Protocol Progress Committee (PPC) comprise the Protocol Review and Monitoring System (PRMS) for the Indiana University Melvin and Bren Simon Cancer Center (IUSCC). The SRC and PPC focus on the following three specific aims:
Aim 1 : To ensure the IUSCC prioritizes and conducts impactful trials with high scientific merit. The IUSCC prioritizes Investigator Initiated Trials (IITs) > national cooperative group > industry-sponsored trials. Initial responsibility for prioritization rests with the disease-oriented teams (DOTs). DOTs review proposed trials in the context of their programmatic goals and their current trial portfolio. In addition, DOTs analyze patient volumes and accrual to current/recent trials to ensure the accrual goals are reasonable and adequate. Once a DOT has agreed to support a trial, the full protocol, consent, and all supporting documents, along with the feasibility checklist and prioritization scorecard are submitted to the SRC for review. SRC review focuses on scientific merit, but also ensures that the DOTs have appropriately prioritized trials and managed any conflicts. Trials submitted to the SRC by an investigator or DOT that has had a trial closed for low accrual within the previous three years require additional justification of the accrual estimates.
Aim2 : To facilitate rapid activation by conducting efficient and timely review of new protocols. The goal of the PRMS is to conduct reviews in an efficient and timely manner to support rapid activation of high priority trials. To enhance efficiency, beginning in January 2018 the SRC meets twice a month. The SRC uses e-PRMS, a paperless committee management system which is housed within OnCore. The online submission and review console offers immediate access to electronic protocol documents, eliminating the need to track, copy, and collate multiple binders for reviewers. Reviewers submit comments at least 48 hours prior to the meeting which are forwarded to the PI, who can respond prior to the meeting if possible. Concurrent scientific and feasibility review facilitates rapid activation while minimizing resource utilization until feasibility is assured.
Aim 3 : To maximize the use of resources by monitoring protocol accrual and progress. Once approved, the PPC monitors protocol progress and accrual. Protocols not reaching the minimum accrual target are subject to closure by the PPC. High priority IITs and trials in rare populations are granted additional time to meet accrual goals, but still must make progress to avoid closure. The PPC is a subcommittee of the SRC and meets concurrently with the SRC, increasing reviewers' awareness of the resources lost to low accruing trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082709-21
Application #
9987565
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1999-09-22
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10
Filley, Anna; Henriquez, Mario; Bhowmik, Tanmoy et al. (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 137:469-479
Sishtla, Kamakshi; Pitt, Natalie; Shadmand, Mehdi et al. (2018) Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14. Sci Rep 8:16152
Koh, Byunghee; Abdul Qayum, Amina; Srivastava, Rajneesh et al. (2018) A conserved enhancer regulates Il9 expression in multiple lineages. Nat Commun 9:4803
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559

Showing the most recent 10 out of 256 publications